CoreValve is poised to become a global leader in percutaneous and transapical aortic valve replacement. I'm very excited about the opportunity to work with the CoreValve team to help the company realize its enormous potential
IRVINE, Calif. (PRWEB) October 9, 2008
Frank Fischer has more than 25 years of senior management experience in the medical device industry. He has served on the NeuroPace Board of Directors since 1998 and joined the Company as its CEO in January 2000. Prior to joining NeuroPace, Mr. Fischer was President, CEO and Director of Heartport, Inc., a minimally invasive cardiac surgery company. Previously, Mr. Fischer was President, CEO and Director of Ventritex, Inc., a company that pioneered implantable cardiac defibrillators. Before joining Ventritex, he spent 10 years in various management positions at Cordis Corporation in the cardiac and neurosurgical device areas, serving most recently as President of the Implantable Products Division. Mr. Fischer holds a Bachelor of Science in Mechanical Engineering and a Master of Science in Management degrees from Rensselaer Polytechnic Institute.
"CoreValve is poised to become a global leader in percutaneous and transapical aortic valve replacement. I'm very excited about the opportunity to work with the CoreValve team to help the company realize its enormous potential," said Frank Fischer.
"We are very pleased to welcome Frank Fischer as a Director of CoreValve," said Jacques Séguin, M.D., Ph.D., Chairman and Founder. "Frank's experience and expertise will help CoreValve in its mission to extend and improve the quality of life for patients with severe aortic stenosis."
CoreValve, Inc., is headquartered in Irvine, Calif. Its proprietary ReValving® System allows both percutaneous aortic valve replacement (PAVR) and transapical aortic valve replacement (TAVR) and is intended to provide an alternative to open-heart surgery. The ReValving System procedures are performed on the beating heart without cardiac assistance or rapid pacing, and may result in less trauma to the patient. This technology may also offer substantial cost-savings to the healthcare system. The catheter-based technology includes a proprietary framed/self-expanding tissue heart valve that is specifically designed and engineered for transcatheter delivery. For more information about CoreValve, visit the Company's Web site at http://www.corevalve.com.
(Caution: the CoreValve ReValving System will not be available in the USA for clinical trials or for sale until further notice.)